|
Baseline characteristics by treatment group* |
||||
| Treatment Group |
||||
|
|
||||
| Characteristics |
Chloroquine |
Amodiaquine |
Sulphadoxine-Pyrimethamine |
Artesunate-Amodiaquine |
|
|
||||
| No. of patients enrolled |
320 |
385 |
383 |
346 |
| Ejeda |
51 |
51 |
50 |
50 |
| Ihosy |
62 |
62 |
61 |
63 |
| Miandrivazo |
67 |
69 |
69 |
68 |
| Maevatanana |
55 |
56 |
56 |
55 |
| Tsiroanomandidy |
43 |
48 |
48 |
0 |
| Moramanga |
42 |
39 |
40 |
40 |
| Andapa |
0 |
32 |
29 |
41 |
| Farafangana |
0 |
28 |
30 |
29 |
| Age |
||||
| median (range), y |
5 (0.5 – 15) |
5 (0.5 – 15) |
5 (0.5 – 15) |
5 (0.5 – 15) |
| Proportion of children ≤ 5 years |
142 (45.4) |
185 (48.7) |
182 (47.8) |
167 (48.7) |
| Weight, median (IQR), kg |
15 (6 – 58) |
15 (5 – 62) |
14 (6 – 60) |
13 (2.6 – 56) |
| Female |
158 (49.5) |
188 (48.8) |
186 (48.6) |
169 (49.0) |
| Temperature, mean (95% CI) |
38.4 (38.3 – 38.5) |
38.4 (38.3 – 38.5) |
38.4 (38.3 – 38.5) |
38.6 (38.5 – 38.7) |
| Trophozoite density, geometric mean (range), parasite/μl |
15,302 (1,241 – 200,000) |
133,068 (1,000 – 194,000) |
13,880 (1,000 – 196,000) |
14,346 (1669 – 192000) |
| Haemoglobin, median (IQR), g/dL |
10.1 (5.3 – 15.8) |
10.2 (5.8 – 15.6) |
10.0 (5.6 – 14.7) |
10.1 (5.1 – 14.5) |
| Anemic at enrollment± |
107 (39.3) |
114 (34.5) |
127 (38.5) |
103 (35.4) |
|
Abbreviations: CI, confidence interval; IQR, interquartile range. *Data are presented as No. (%) unless otherwise indicated. †Anaemia defined as haemoglobin of less than 10 g/dL. | ||||
Ménard et al. Malaria Journal 2008 7:55 doi:10.1186/1475-2875-7-55 |
||||